Kirsten Krohg-Sørensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kirsten Krohg-Sørensen has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Mona Skjelland
Department of Neurology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
19 shared publications David Russell
Department of Neurology, Oslo University Hospital Rikshospitalet, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
14 shared publicationsPål Aukrust
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway
12 shared publicationsBente Halvorsen
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway
10 shared publicationsAnnika E. Michelsen
8 shared publicationsSverre Holm
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
8 shared publications
Latest Publications
- 1 November 2017
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 66 (5) , 1627
The National Norwegian Carotid Study: Time from Symptom Onset to Surgery is too Long, Resulting in Additional Neurological Events
- 1 November 2017
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 66 (5) , 1627
The National Norwegian Carotid Study: Time from Symptom Onset to Surgery is too Long, Resulting in Additional Neurological Events
- Open Access
- 1 October 2017
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 54 (4) , 415-422
Editor's Choice – The National Norwegian Carotid Study: Time from Symptom Onset to Surgery is too Long, Resulting in Additional Neurological Events
- 1 October 2017
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 54 (4) , 415-422
Open AccessEditor's Choice – The National Norwegian Carotid Study: Time from Symptom Onset to Surgery is too Long, Resulting in Additional Neurological Events
- 24 May 2017
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 52 (6) , 1125-1131
Cardiovascular surgery in Loeys–Dietz syndrome types 1–4
OBJECTIVES: The first publication of Loeys–Dietz syndrome (LDS) described aortic rupture at young ages. Experience with new LDS types showed that the clinical course varies, and thresholds for prophylactic surgery are discussed. As this is an uncommon disease, experience needs to be shared. METHODS: Retrospective review of patients with LDS types 1–4 undergoing cardiovascular surgery during the years 1991–2016. RESULTS: Thirty-five patients (including 6 children with LDS2) underwent 57 operations. LDS 1, 2, 3 and 4 included 4, 17, 11 and 3 patients, respectively. Mean age at first surgery was 36 years, with a non-significant trend that LDS2 patients were younger. Of the 9 emergency surgeries, 7 were type A dissections, with 1 postoperative death. Twenty-two patients had prophylactic aortic root surgery (17 valve-sparing root replacements), with 1 postoperative death, 1 reoperation with valve replacement and 1 late death. Freedom from root reintervention and death was 92% at 13 years. Of the 11 patients with LDS3, 5 needed mitral valve surgery. Mitral valve disease was not found in the other LDS types. Ten patients needed >1 operation. Of the 57 operations, 33 were in the ascending aorta, 20 in the aorta distal to the arch including branches and 4 were isolated heart surgeries. Of the 20 vascular operations, 16 were in LDS2. Cumulative survival 20 years after first surgery (all patients) was 94.3%. CONCLUSIONS: Clinical course seems to be more aggressive in LDS2, with index operation at a younger age, and higher risk of needing several operations. Vascular disease distal to the arch is not uncommon. LDS3 seems to be associated with mitral valve disease. Prophylactic aortic root surgery is safe and durable.
- 24 May 2017
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 52 (6) , 1125-1131
Cardiovascular surgery in Loeys–Dietz syndrome types 1–4
OBJECTIVES: The first publication of Loeys–Dietz syndrome (LDS) described aortic rupture at young ages. Experience with new LDS types showed that the clinical course varies, and thresholds for prophylactic surgery are discussed. As this is an uncommon disease, experience needs to be shared. METHODS: Retrospective review of patients with LDS types 1–4 undergoing cardiovascular surgery during the years 1991–2016. RESULTS: Thirty-five patients (including 6 children with LDS2) underwent 57 operations. LDS 1, 2, 3 and 4 included 4, 17, 11 and 3 patients, respectively. Mean age at first surgery was 36 years, with a non-significant trend that LDS2 patients were younger. Of the 9 emergency surgeries, 7 were type A dissections, with 1 postoperative death. Twenty-two patients had prophylactic aortic root surgery (17 valve-sparing root replacements), with 1 postoperative death, 1 reoperation with valve replacement and 1 late death. Freedom from root reintervention and death was 92% at 13 years. Of the 11 patients with LDS3, 5 needed mitral valve surgery. Mitral valve disease was not found in the other LDS types. Ten patients needed >1 operation. Of the 57 operations, 33 were in the ascending aorta, 20 in the aorta distal to the arch including branches and 4 were isolated heart surgeries. Of the 20 vascular operations, 16 were in LDS2. Cumulative survival 20 years after first surgery (all patients) was 94.3%. CONCLUSIONS: Clinical course seems to be more aggressive in LDS2, with index operation at a younger age, and higher risk of needing several operations. Vascular disease distal to the arch is not uncommon. LDS3 seems to be associated with mitral valve disease. Prophylactic aortic root surgery is safe and durable.
- 1 August 2016
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 97, 386-397
Enhanced base excision repair capacity in carotid atherosclerosis may protect nuclear DNA but not mitochondrial DNA
- 1 August 2016
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 97, 386-397
Enhanced base excision repair capacity in carotid atherosclerosis may protect nuclear DNA but not mitochondrial DNA
- Open Access
- 22 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 28337
Neil3-dependent base excision repair regulates lipid metabolism and prevents atherosclerosis in Apoe-deficient mice
Increasing evidence suggests that oxidative DNA damage accumulates in atherosclerosis. Recently, we showed that a genetic variant in the human DNA repair enzyme NEIL3 was associated with increased risk of myocardial infarction. Here, we explored the role of Neil3/NEIL3 in atherogenesis by both clinical and experimental approaches. Human carotid plaques revealed increased NEIL3 mRNA expression which significantly correlated with mRNA levels of the macrophage marker CD68. Apoe−/−Neil3−/− mice on high-fat diet showed accelerated plaque formation as compared to Apoe−/− mice, reflecting an atherogenic lipid profile, increased hepatic triglyceride levels and attenuated macrophage cholesterol efflux capacity. Apoe−/−Neil3−/− mice showed marked alterations in several pathways affecting hepatic lipid metabolism, but no genotypic alterations in genome integrity or genome-wide accumulation of oxidative DNA damage. These results suggest a novel role for the DNA glycosylase Neil3 in atherogenesis in balancing lipid metabolism and macrophage function, potentially independently of genome-wide canonical base excision repair of oxidative DNA damage.
- 22 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 28337
Open AccessNeil3-dependent base excision repair regulates lipid metabolism and prevents atherosclerosis in Apoe-deficient mice
Increasing evidence suggests that oxidative DNA damage accumulates in atherosclerosis. Recently, we showed that a genetic variant in the human DNA repair enzyme NEIL3 was associated with increased risk of myocardial infarction. Here, we explored the role of Neil3/NEIL3 in atherogenesis by both clinical and experimental approaches. Human carotid plaques revealed increased NEIL3 mRNA expression which significantly correlated with mRNA levels of the macrophage marker CD68. Apoe−/−Neil3−/− mice on high-fat diet showed accelerated plaque formation as compared to Apoe−/− mice, reflecting an atherogenic lipid profile, increased hepatic triglyceride levels and attenuated macrophage cholesterol efflux capacity. Apoe−/−Neil3−/− mice showed marked alterations in several pathways affecting hepatic lipid metabolism, but no genotypic alterations in genome integrity or genome-wide accumulation of oxidative DNA damage. These results suggest a novel role for the DNA glycosylase Neil3 in atherogenesis in balancing lipid metabolism and macrophage function, potentially independently of genome-wide canonical base excision repair of oxidative DNA damage.
- 24 May 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (8) , 2004-2010
Semiautomated Magnetic Resonance Imaging Assessment of Carotid Plaque Lipid Content
- 24 May 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (8) , 2004-2010
Semiautomated Magnetic Resonance Imaging Assessment of Carotid Plaque Lipid Content
- Open Access
- 6 May 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (5)
NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis
Background: The NLR family, pyrin domain containing 3 ( NLRP 3) inflammasome is an interleukin ( IL )‐1β and IL ‐18 cytokine processing complex that is activated in inflammatory conditions. The role of the NLRP 3 inflammasome in the pathogenesis of atherosclerosis and myocardial infarction is not fully understood. Methods and Results: Atherosclerotic plaques were analyzed for transcripts of the NLRP 3 inflammasome, and for IL ‐1β release. The Swedish First‐ever myocardial Infarction study in Ac‐county ( FIA ) cohort consisting of DNA from 555 myocardial infarction patients and 1016 healthy individuals was used to determine the frequency of 4 single nucleotide polymorphisms ( SNP s) from the downstream regulatory region of NLRP 3. Expression of NLRP 3, Apoptosis‐associated speck‐like protein containing a CARD ( ASC ), caspase‐1 ( CASP 1), IL 1B, and IL 18 mRNA was significantly increased in atherosclerotic plaques compared to normal arteries. The expression of NLRP 3 mRNA was significantly higher in plaques of symptomatic patients when compared to asymptomatic ones. CD 68‐positive macrophages were observed in the same areas of atherosclerotic lesions as NLRP 3 and ASC expression. Occasionally, expression of NLRP 3 and ASC was also present in smooth muscle cells. Cholesterol crystals and ATP induced IL ‐1β release from lipopolysaccharide‐primed human atherosclerotic lesion plaques. The minor alleles of the variants rs4266924, rs6672995, and rs10733113 were associated with NLRP 3 mRNA levels in peripheral blood mononuclear cells but not with the risk of myocardial infarction. Conclusions: Our results indicate a possible role of the NLRP 3 inflammasome and its genetic variants in the pathogenesis of atherosclerosis.
- 6 May 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (5)
Open AccessNLRP3 Inflammasome Expression and Activation in Human Atherosclerosis
Background: The NLR family, pyrin domain containing 3 ( NLRP 3) inflammasome is an interleukin ( IL )‐1β and IL ‐18 cytokine processing complex that is activated in inflammatory conditions. The role of the NLRP 3 inflammasome in the pathogenesis of atherosclerosis and myocardial infarction is not fully understood. Methods and Results: Atherosclerotic plaques were analyzed for transcripts of the NLRP 3 inflammasome, and for IL ‐1β release. The Swedish First‐ever myocardial Infarction study in Ac‐county ( FIA ) cohort consisting of DNA from 555 myocardial infarction patients and 1016 healthy individuals was used to determine the frequency of 4 single nucleotide polymorphisms ( SNP s) from the downstream regulatory region of NLRP 3. Expression of NLRP 3, Apoptosis‐associated speck‐like protein containing a CARD ( ASC ), caspase‐1 ( CASP 1), IL 1B, and IL 18 mRNA was significantly increased in atherosclerotic plaques compared to normal arteries. The expression of NLRP 3 mRNA was significantly higher in plaques of symptomatic patients when compared to asymptomatic ones. CD 68‐positive macrophages were observed in the same areas of atherosclerotic lesions as NLRP 3 and ASC expression. Occasionally, expression of NLRP 3 and ASC was also present in smooth muscle cells. Cholesterol crystals and ATP induced IL ‐1β release from lipopolysaccharide‐primed human atherosclerotic lesion plaques. The minor alleles of the variants rs4266924, rs6672995, and rs10733113 were associated with NLRP 3 mRNA levels in peripheral blood mononuclear cells but not with the risk of myocardial infarction. Conclusions: Our results indicate a possible role of the NLRP 3 inflammasome and its genetic variants in the pathogenesis of atherosclerosis.
- 1 February 2016
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 51 (2) , 194-201
Trends in Abdominal Aortic and Iliac Aneurysm Repairs in Norway from 2001 to 2013
- 1 February 2016
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 51 (2) , 194-201
Trends in Abdominal Aortic and Iliac Aneurysm Repairs in Norway from 2001 to 2013
- Open Access
- 1 November 2015
- Published by Elsevier in Atherosclerosis
- Vol. 243 (1) , 204-210
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages
- 1 November 2015
- Published by Elsevier in Atherosclerosis
- Vol. 243 (1) , 204-210
Open AccessIncreased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages
- 1 March 2015
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (3) , 793-799
Interleukin 23 Levels Are Increased in Carotid Atherosclerosis
Background and Purpose—: Interleukin (IL)-23 is a cytokine in the IL-12 family, mainly produced by antigen-presenting cells with a central role in inflammation. We hypothesize that IL-23 is also important in atherogenesis and investigate this in a population with carotid atherosclerosis. Methods—: Plasma levels of IL-23 were measured in patients with carotid artery stenosis and in healthy controls. The mRNA levels of IL-23 and its receptor, IL-23R, were measured in atherosclerotic plaques, nonatherosclerotic vessels, peripheral blood mononuclear cells, and plasmacytoid dendritic cells. Results—: Our findings were as follows: (1) patients with carotid atherosclerosis (n=177) had significantly raised plasma levels of IL-23 when compared with healthy controls (n=24) with particularly high levels in those with the most recent symptoms. (2) mRNA levels of IL-23 and IL-23R were markedly increased in carotid plaques (n=68) when compared with nonatherosclerotic vessels (n=8–10). Immunostaining showed colocalization to plaque macrophages. (3) Patients with carotid atherosclerosis had increased mRNA levels of both IL-23 and IL-23R in plasmacytoid dendritic cells, but not in peripheral blood mononuclear cells. (4) IL-23 increased IL-17 release in monocytes and particularly in peripheral blood mononuclear cells from patients with carotid atherosclerosis, but not in cells from healthy controls. (5) IL-23 gave a prominent tumor necrosis factor release in monocytes from patients with carotid atherosclerosis but not in cells from healthy controls. (6) High plasma levels of IL-23 were associated with increased mortality during follow-up. Conclusions—: We have shown an association between IL-23 and disease progression in patients with carotid atherosclerosis, potentially involving IL-17-related mechanisms.
- 1 March 2015
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (3) , 793-799
Interleukin 23 Levels Are Increased in Carotid Atherosclerosis
Background and Purpose—: Interleukin (IL)-23 is a cytokine in the IL-12 family, mainly produced by antigen-presenting cells with a central role in inflammation. We hypothesize that IL-23 is also important in atherogenesis and investigate this in a population with carotid atherosclerosis. Methods—: Plasma levels of IL-23 were measured in patients with carotid artery stenosis and in healthy controls. The mRNA levels of IL-23 and its receptor, IL-23R, were measured in atherosclerotic plaques, nonatherosclerotic vessels, peripheral blood mononuclear cells, and plasmacytoid dendritic cells. Results—: Our findings were as follows: (1) patients with carotid atherosclerosis (n=177) had significantly raised plasma levels of IL-23 when compared with healthy controls (n=24) with particularly high levels in those with the most recent symptoms. (2) mRNA levels of IL-23 and IL-23R were markedly increased in carotid plaques (n=68) when compared with nonatherosclerotic vessels (n=8–10). Immunostaining showed colocalization to plaque macrophages. (3) Patients with carotid atherosclerosis had increased mRNA levels of both IL-23 and IL-23R in plasmacytoid dendritic cells, but not in peripheral blood mononuclear cells. (4) IL-23 increased IL-17 release in monocytes and particularly in peripheral blood mononuclear cells from patients with carotid atherosclerosis, but not in cells from healthy controls. (5) IL-23 gave a prominent tumor necrosis factor release in monocytes from patients with carotid atherosclerosis but not in cells from healthy controls. (6) High plasma levels of IL-23 were associated with increased mortality during follow-up. Conclusions—: We have shown an association between IL-23 and disease progression in patients with carotid atherosclerosis, potentially involving IL-17-related mechanisms.